Alexion, BioMarin raise 2014 guidance

Rare disease specialists Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) and BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) both raised 2014 guidance in earnings reports on Thursday.

Alexion shares added $12.65 to $185.92 after the company raised its revenue guidance from $2.18-$2.20 billion to $2.22-$2.25 billion and its non-GAAP EPS guidance from $4.95-$5.05 to $5.15-$5.20. ...